참고문헌
- Sagar S, Liu PP, Cooper LT Jr. Myocarditis. Lancet 2012;379:738-47. https://doi.org/10.1016/S0140-6736(11)60648-X
- Heymans S, Eriksson U, Lehtonen J, Cooper LT Jr. The quest for new approaches in myocarditis and inflammatory cardiomyopathy. J Am Coll Cardiol 2016;68:2348-64. https://doi.org/10.1016/j.jacc.2016.09.937
- Chen HS, Wang W, Wu SN, Liu JP. Corticosteroids for viral myocarditis. Cochrane Database Syst Rev 2013;2013:CD004471.
- Robinson J, Hartling L, Vandermeer B, Klassen TP. Intravenous immunoglobulin for presumed viral myocarditis in children and adults. Cochrane Database Syst Rev 2015;5:CD004370.
- Lv S, Yuan P, Dong J, et al. QiShenYiQi pill improves the reparative myocardial fibrosis by regulating autophagy. J Cell Mol Med 2020;24:11283-93. https://doi.org/10.1111/jcmm.15695
- Bramuzzo M, Ventura A, Martelossi S, Lazzerini M. Thalidomide for inflammatory bowel disease: systematic review. Medicine (Baltimore) 2016;95:e4239.
- Chasset F, Tounsi T, Cesbron E, Barbaud A, Frances C, Arnaud L. Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: a systematic review and meta-analysis. J Am Acad Dermatol 2018;78:342-350.e4. https://doi.org/10.1016/j.jaad.2017.09.059
- Raje N, Anderson K. Thalidomide--a revival story. N Engl J Med 1999;341:1606-9. https://doi.org/10.1056/NEJM199911183412110
- Kim DH, Kim YJ, Chang SA, et al. The protective effect of thalidomide on left ventricular function in a rat model of diabetic cardiomyopathy. Eur J Heart Fail 2010;12:1051-60. https://doi.org/10.1093/eurjhf/hfq103
- Yazbeck R, Howarth GS, Abbott CA. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends Pharmacol Sci 2009;30:600-7. https://doi.org/10.1016/j.tips.2009.08.003
- Kodama M, Matsumoto Y, Fujiwara M, Masani F, Izumi T, Shibata A. A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clin Immunol Immunopathol 1990;57:250-62. https://doi.org/10.1016/0090-1229(90)90039-S
- Yuan Z, Kishimoto C, Shioji K. Beneficial effects of low-dose benidipine in acute autoimmune myocarditis: suppressive effects on inflammatory cytokines and inducible nitric oxide synthase. Circ J 2003;67:545-50. https://doi.org/10.1253/circj.67.545
- Tang ST, Su H, Zhang Q, et al. Sitagliptin inhibits endothelin-1 expression in the aortic endothelium of rats with streptozotocin-induced diabetes by suppressing the nuclear factor-κB/IκBα system through the activation of AMP-activated protein kinase. Int J Mol Med 2016;37:1558-66. https://doi.org/10.3892/ijmm.2016.2578
- Zhang S, Kodama M, Hanawa H, Izumi T, Shibata A, Masani F. Effects of cyclosporine, prednisolone and aspirin on rat autoimmune giant cell myocarditis. J Am Coll Cardiol 1993;21:1254-60. https://doi.org/10.1016/0735-1097(93)90254-X
- Kodama M, Izumi T. Experimental autoimmune myocarditis. Acta Med Biol (Niigata) 1991;39:1-10.
- Okura Y, Yamamoto T, Goto S, et al. Characterization of cytokine and iNOS mRNA expression in situ during the course of experimental autoimmune myocarditis in rats. J Mol Cell Cardiol 1997;29:491-502. https://doi.org/10.1006/jmcc.1996.0293
- Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012;26:2326-35. https://doi.org/10.1038/leu.2012.119
- Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004;4:314-22. https://doi.org/10.1038/nrc1323
- Yndestad A, Vinge LE, Bjornerheim R, et al. Thalidomide attenuates the development of fibrosis during post-infarction myocardial remodelling in rats. Eur J Heart Fail 2006;8:790-6. https://doi.org/10.1016/j.ejheart.2006.02.007
- Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity. Science 2010;327:1345-50. https://doi.org/10.1126/science.1177319
- Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma 2013;54:683-7. https://doi.org/10.3109/10428194.2012.728597
- Neu N, Rose NR, Beisel KW, Herskowitz A, Gurri-Glass G, Craig SW. Cardiac myosin induces myocarditis in genetically predisposed mice. J Immunol 1987;139:3630-6. https://doi.org/10.4049/jimmunol.139.11.3630
- Schon E, Demuth HU, Eichmann E, et al. Dipeptidyl peptidase IV in human T lymphocytes. Impaired induction of interleukin 2 and gamma interferon due to specific inhibition of dipeptidyl peptidase IV. Scand J Immunol 1989;29:127-32. https://doi.org/10.1111/j.1365-3083.1989.tb01108.x
- Pitman MR, Sulda ML, Kuss B, Abbott CA. Dipeptidyl peptidase 8 and 9--guilty by association? Front Biosci (Landmark Ed) 2009;14:3619-33. https://doi.org/10.2741/3476
- Zheng SL, Roddick AJ, Aghar-Jaffar R, et al. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA 2018;319:1580-91. https://doi.org/10.1001/jama.2018.3024
- Abrahami D, Douros A, Yin H, et al. Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. BMJ 2018;360:k872.
- Fadini GP, Avogaro A. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul Pharmacol 2011;55:10-6. https://doi.org/10.1016/j.vph.2011.05.001
- Hirakawa H, Zempo H, Ogawa M, et al. A DPP-4 inhibitor suppresses fibrosis and inflammation on experimental autoimmune myocarditis in mice. PLoS One 2015;10:e0119360.
- Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005;54:146-51. https://doi.org/10.2337/diabetes.54.1.146
- Timmers L, Henriques JP, de Kleijn DP, et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009;53:501-10. https://doi.org/10.1016/j.jacc.2008.10.033